ANTKMT

Summary

ANTKMT (adenine nucleotide translocase lysine methyltransferase, HGNC:14152) is a protein-coding gene on chromosome 16p13.3, encoding Adenine nucleotide translocase lysine N-methyltransferase (Q9BQD7). Mitochondrial protein-lysine N-methyltransferase that trimethylates adenine nucleotide translocases ANT2/SLC25A5 and ANT3/SLC25A6, thereby regulating mitochondrial respiration.

Enables protein-lysine N-methyltransferase activity. Involved in peptidyl-lysine trimethylation. Located in mitochondrion.

Source: NCBI Gene 65990 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 103 total — 17 pathogenic
• MANE Select transcript: NM_023933

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14152
Approved symbol	ANTKMT
Name	adenine nucleotide translocase lysine methyltransferase
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC2494
Ensembl gene	ENSG00000103254
Ensembl biotype	protein_coding
OMIM	618566
Entrez	65990

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 4 retained_intron

ENST00000219535, ENST00000564000, ENST00000564640, ENST00000566437, ENST00000566525, ENST00000568916, ENST00000569529, ENST00000570237, ENST00000853259, ENST00000853260, ENST00000853261

RefSeq mRNA: 2 — MANE Select: NM_023933 NM_001271285, NM_023933

CCDS: CCDS10423, CCDS59254

Canonical transcript exons

ENST00000569529 — 5 exons

Exon	Start	End
ENSE00000664194	722084	722134
ENSE00000664195	721801	721941
ENSE00002611837	721146	721436
ENSE00003471140	722309	722590
ENSE00003680095	721598	721702

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 94.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.5084 / max 139.3693, expressed in 1803 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
151983	11.7178	1795
151985	1.1189	329
151984	0.5788	233
151986	0.5338	186
151982	0.4840	213
151987	0.0515	10
151988	0.0237	8

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
anterior cingulate cortex	UBERON:0009835	94.30	gold quality
cingulate cortex	UBERON:0003027	94.22	gold quality
mucosa of transverse colon	UBERON:0004991	93.85	gold quality
right testis	UBERON:0004534	93.65	gold quality
right frontal lobe	UBERON:0002810	93.60	gold quality
left testis	UBERON:0004533	93.59	gold quality
amygdala	UBERON:0001876	93.47	gold quality
apex of heart	UBERON:0002098	93.13	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.97	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.86	gold quality
prefrontal cortex	UBERON:0000451	92.43	gold quality
adenohypophysis	UBERON:0002196	92.23	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.14	gold quality
testis	UBERON:0000473	91.12	gold quality
pituitary gland	UBERON:0000007	90.99	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.76	gold quality
neocortex	UBERON:0001950	90.70	gold quality
frontal cortex	UBERON:0001870	90.40	gold quality
granulocyte	CL:0000094	90.39	gold quality
right lobe of liver	UBERON:0001114	90.13	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.75	gold quality
metanephros cortex	UBERON:0010533	89.55	gold quality
cerebral cortex	UBERON:0000956	89.33	gold quality
spinal cord	UBERON:0002240	89.26	gold quality
right adrenal gland	UBERON:0001233	89.06	gold quality
right adrenal gland cortex	UBERON:0035827	88.85	gold quality
cerebellar hemisphere	UBERON:0002245	88.76	gold quality
cerebellar cortex	UBERON:0002129	88.69	gold quality
left adrenal gland	UBERON:0001234	88.64	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.94

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 1)

• FAM173A is the long-sought mitochondrial lysine-specific methyltransferase responsible for adenine nucleotide translocase methylation at Lys-52, and point out the functional significance of Lys-52 methylation in adenine nucleotide translocase. (PMID:31213526)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	antkmt	ENSDARG00000041223
mus_musculus	Antkmt	ENSMUSG00000057411
rattus_norvegicus	Antkmt	ENSRNOG00000019684
drosophila_melanogaster	CG3337	FBGN0038871
caenorhabditis_elegans		WBGENE00012658

Paralogs (1): ATPSCKMT (ENSG00000150756)

Protein

Protein identifiers

Adenine nucleotide translocase lysine N-methyltransferase — Q9BQD7 (reviewed: Q9BQD7)

All UniProt accessions (4): Q9BQD7, H3BPE8, H3BQW1, J3KMW5

UniProt curated annotations — full annotation on UniProt →

Function. Mitochondrial protein-lysine N-methyltransferase that trimethylates adenine nucleotide translocases ANT2/SLC25A5 and ANT3/SLC25A6, thereby regulating mitochondrial respiration. Probably also trimethylates ANT1/SLC25A4.

Subcellular location. Mitochondrion membrane.

Domain organisation. The pre-methyltransferase (preMT) region is responsible for mitochondrial localization.

Similarity. Belongs to the ANT/ATPSC lysine N-methyltransferase family.

RefSeq proteins (2): NP_001258214, NP_076422* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026170	FAM173A/B	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Catalyzed reactions (Rhea), 1 shown:

• L-lysyl-[protein] + 3 S-adenosyl-L-methionine = N(6),N(6),N(6)-trimethyl-L-lysyl-[protein] + 3 S-adenosyl-L-homocysteine + 3 H(+) (RHEA:54192)

UniProt features (9 total): region of interest 4, mutagenesis site 3, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQD7-F1	82.01	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (3):

Position	Phenotype
1–76	abolished mitochondrial localization.
1–42	does not affect mitochondrial localization.
105	abolished methyltransferase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 145 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_ATP_BIOSYNTHETIC_PROCESS, GOBP_OXIDATIVE_PHOSPHORYLATION, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_TRIPHOSPHATE_BIOSYNTHETIC_PROCESS, GOCC_MITOCHONDRIAL_ENVELOPE, P300_01

GO Biological Process (3): peptidyl-lysine trimethylation (GO:0018023), regulation of mitochondrial ATP synthesis coupled proton transport (GO:1905706), methylation (GO:0032259)

GO Molecular Function (4): protein-lysine N-methyltransferase activity (GO:0016279), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial membrane (GO:0031966), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidyl-lysine methylation	1
proton motive force-driven mitochondrial ATP synthesis	1
regulation of ATP biosynthetic process	1
metabolic process	1
protein methyltransferase activity	1
lysine N-methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrion	1
mitochondrial envelope	1
organelle membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANTKMT	SLC38A12	Q8NE00	557
ANTKMT	CRAMP1	Q96RY5	535
ANTKMT	TSR3	Q9UJK0	531
ANTKMT	EEF1AKMT1	Q8WVE0	528
ANTKMT	OXLD1	Q5BKU9	505
ANTKMT	METTL18	O95568	501
ANTKMT	METTL21A	Q8WXB1	489
ANTKMT	ETFBKMT	Q8IXQ9	469
ANTKMT	VCPKMT	Q9H867	468
ANTKMT	PRORP	O15091	465
ANTKMT	EEF2KMT	Q96G04	464
ANTKMT	TMEM242	Q9NWH2	457
ANTKMT	METTL22	Q9BUU2	438
ANTKMT	METTL23	Q86XA0	434
ANTKMT	EEF1AKMT2	Q5JPI9	429

IntAct

59 interactions, top by confidence:

A	B	Type	Score
CTNNA3	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
PPP1R16A	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
DTX2	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
HGS	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
ANTKMT	CTNNA3	psi-mi:“MI:0915”(physical association)	0.560
ZNF76	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
PIK3R3	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
BANP	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
ANTKMT	FANCL	psi-mi:“MI:0915”(physical association)	0.560
HDAC7	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
ANTKMT	PARVG	psi-mi:“MI:0915”(physical association)	0.560
EFCAB2	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
ANTKMT	AIRIM	psi-mi:“MI:0915”(physical association)	0.560
CCDC24	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
MEIS2	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
MKRN3	ANTKMT	psi-mi:“MI:0915”(physical association)	0.560
SLC1A2	UBXN8	psi-mi:“MI:0914”(association)	0.350
BANP	ANTKMT	psi-mi:“MI:0915”(physical association)	0.000
FANCL	ANTKMT	psi-mi:“MI:0915”(physical association)	0.000
HDAC7	ANTKMT	psi-mi:“MI:0915”(physical association)	0.000
PARVG	ANTKMT	psi-mi:“MI:0915”(physical association)	0.000
EFCAB2	ANTKMT	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (27): FAM173A (Two-hybrid), LUC7L (Two-hybrid), FAM173A (Two-hybrid), FAM173A (Two-hybrid), HAP1 (Two-hybrid), IMMT (Two-hybrid), LUC7L2 (Two-hybrid), PFN2 (Two-hybrid), SH3GL3 (Two-hybrid), TP53 (Two-hybrid), FANCL (Two-hybrid), C1orf109 (Two-hybrid), PIK3R3 (Two-hybrid), MEIS2 (Two-hybrid), PARVG (Two-hybrid)

ESM2 similar proteins: A2AA28, A4FV42, A4FV98, A6NDG6, D3YWP0, D3ZVU9, O15315, O35719, O70277, O75382, O94759, P21964, P57775, P81799, Q2TBS1, Q3UGX3, Q4R3I0, Q5E9V4, Q5H879, Q5RJL2, Q5SUV1, Q6DC64, Q7Z624, Q86WI3, Q86XA0, Q8BNV1, Q8C436, Q8CIW5, Q8IZ69, Q8N8L6, Q8N9F0, Q8VCX6, Q8WXB1, Q96AZ1, Q96FB5, Q96RR1, Q9BQD7, Q9BRQ3, Q9BUU2, Q9CQL0

Diamond homologs: D3ZLY0, Q501J2, Q5I047, Q6P4H8, Q9BQD7, Q9D1Z3, Q9XX11, F0NBH8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	17
Likely pathogenic	0
Uncertain significance	67
Likely benign	5
Benign	6

Top pathogenic / likely-pathogenic (17)

Variant ID	HGVS	Classification
145576	GRCh38/hg38 16p13.3(chr16:46766-1544014)x1	Pathogenic
148760	GRCh38/hg38 16p13.3(chr16:46722-1867327)x1	Pathogenic
148917	GRCh38/hg38 16p13.3(chr16:46766-882211)x1	Pathogenic
152879	GRCh38/hg38 16p13.3(chr16:59980-1221651)x1	Pathogenic
1808731	GRCh37/hg19 16p13.3(chr16:85881-1350186)x1	Pathogenic
2685536	GRCh37/hg19 16p13.3(chr16:85881-1657611)x1	Pathogenic
3243622	NC_000016.9:g.(?256302)(1557737_?)del	Pathogenic
564251	GRCh37/hg19 16p13.3(chr16:85880-1498731)x1	Pathogenic
564252	GRCh37/hg19 16p13.3(chr16:85880-1875694)x1	Pathogenic
59410	GRCh38/hg38 16p13.3(chr16:23141-1712523)x1	Pathogenic
59411	GRCh38/hg38 16p13.3(chr16:46766-1997582)x1	Pathogenic
59425	GRCh38/hg38 16p13.3(chr16:105429-1499893)x1	Pathogenic
655214	NC_000016.9:g.(?624055)(2115656_?)del	Pathogenic
685952	GRCh37/hg19 16p13.3(chr16:85880-830613)x1	Pathogenic
687431	GRCh37/hg19 16p13.3(chr16:85880-1468459)x1	Pathogenic
688348	GRCh37/hg19 16p13.3(chr16:85880-2053328)x1	Pathogenic
815766	GRCh37/hg19 16p13.3(chr16:85880-1166355)x1	Pathogenic

SpliceAI

435 predictions. Top by Δscore:

Variant	Effect	Δscore
16:721698:GGATC:G	donor_gain	1.0000
16:721699:GATC:G	donor_gain	1.0000
16:721699:GATCG:G	donor_gain	1.0000
16:721700:ATCGT:A	donor_loss	1.0000
16:721701:TC:T	donor_gain	1.0000
16:721701:TCGT:T	donor_loss	1.0000
16:721702:CGT:C	donor_loss	1.0000
16:721703:G:GG	donor_gain	1.0000
16:721704:T:G	donor_loss	1.0000
16:721700:A:T	donor_gain	0.9900
16:721700:ATC:A	donor_gain	0.9900
16:721705:AA:A	donor_loss	0.9900
16:721938:G:GT	donor_gain	0.9900
16:721939:A:T	donor_gain	0.9900
16:722307:A:AG	acceptor_gain	0.9900
16:722308:G:GG	acceptor_gain	0.9900
16:721795:CCACA:C	acceptor_loss	0.9800
16:721798:CAGGT:C	acceptor_loss	0.9800
16:721799:AGGTG:A	acceptor_loss	0.9800
16:721416:C:T	donor_gain	0.9700
16:721432:TGCAG:T	donor_loss	0.9700
16:721434:CAGG:C	donor_loss	0.9700
16:721435:AG:A	donor_loss	0.9700
16:721436:GGTG:G	donor_loss	0.9700
16:721437:GTG:G	donor_loss	0.9700
16:721438:T:G	donor_loss	0.9700
16:721590:C:CA	acceptor_gain	0.9700
16:722306:CAGC:C	acceptor_loss	0.9700
16:722307:AGCT:A	acceptor_loss	0.9700
16:722308:G:GA	acceptor_loss	0.9700

AlphaMissense

1451 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:722117:T:C	F148L	0.995
16:722119:C:A	F148L	0.995
16:722119:C:G	F148L	0.995
16:722375:T:C	F176L	0.995
16:722377:C:A	F176L	0.995
16:722377:C:G	F176L	0.995
16:721695:G:T	G87V	0.991
16:722329:G:C	K160N	0.990
16:722329:G:T	K160N	0.990
16:722118:T:C	F148S	0.983
16:721695:G:A	G87D	0.981
16:721677:A:G	D81G	0.978
16:721689:G:T	G85V	0.978
16:722107:C:A	N144K	0.978
16:722107:C:G	N144K	0.978
16:721692:A:T	D86V	0.977
16:721938:G:C	W135C	0.976
16:721938:G:T	W135C	0.976
16:721847:A:T	E105V	0.974
16:722118:T:G	F148C	0.974
16:721689:G:A	G85D	0.973
16:721854:C:A	N107K	0.972
16:721854:C:G	N107K	0.972
16:722109:T:A	V145E	0.972
16:722115:T:A	V147E	0.972
16:722327:A:G	K160E	0.971
16:722376:T:C	F176S	0.971
16:721841:G:A	G103D	0.970
16:721802:T:A	V90E	0.968
16:722117:T:A	F148I	0.968

dbSNP variants (sampled 300 via entrez): RS1000199273 (16:722035 C>A,G,T), RS1001191934 (16:719335 C>G), RS1001274325 (16:721476 C>A,G,T), RS1002276684 (16:720500 G>A,C), RS1003000343 (16:719237 C>G,T), RS1003284900 (16:719529 G>A), RS1003317594 (16:719786 A>C,G), RS1003722728 (16:720246 G>A,T), RS1003936146 (16:720440 C>A,T), RS1005201127 (16:719162 A>G), RS1006431047 (16:721304 G>A,T), RS1007043386 (16:721068 C>A,T), RS1007080844 (16:722239 G>C), RS1007784830 (16:720184 C>T), RS1007808946 (16:721109 A>G)

Disease associations

OMIM: gene MIM:618566 | disease phenotypes: MIM:600669, MIM:617027, MIM:613254

GenCC curated gene-disease

Mondo (4): breast ductal adenocarcinoma (MONDO:0005590), idiopathic generalized epilepsy (MONDO:0005579), hyperaldosteronism, familial, type IV (MONDO:0014875), tuberous sclerosis 2 (MONDO:0013199)

Orphanet (2): Familial hyperaldosteronism type IV (Orphanet:642671), Tuberous sclerosis complex (Orphanet:805)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
C562694	Epilepsy, Idiopathic Generalized (supp.)
C566021	Tuberous Sclerosis 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression, increases expression	3
Valproic Acid	increases expression, increases methylation, affects expression	3
sodium arsenite	decreases expression	2
cobaltous chloride	decreases expression	2
dicrotophos	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sulforaphane	decreases expression	1
2-palmitoylglycerol	increases expression	1
jinfukang	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Diazinon	increases methylation	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Methotrexate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1
Vitamin K 3	affects expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SM85	HAP1 FAM173A (-)	Cancer cell line	Male

Clinical trials (associated diseases)

36 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03590197	PHASE4	COMPLETED	Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy
NCT03940326	PHASE4	COMPLETED	Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00150735	PHASE3	COMPLETED	Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
NCT00150748	PHASE3	COMPLETED	Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
NCT03678753	PHASE3	COMPLETED	Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
NCT05147571	PHASE3	ACTIVE_NOT_RECRUITING	RNS System NAUTILUS Study
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT06908356	PHASE2	RECRUITING	An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT02201212	PHASE2	COMPLETED	Everolimus for Cancer With TSC1 or TSC2 Mutation
NCT05103358	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery
NCT06425159	PHASE2/PHASE3	TERMINATED	A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
NCT00001325	Not specified	COMPLETED	Metabolic Abnormalities in Children With Epilepsy
NCT00916903	Not specified	TERMINATED	Genetic Disease Gene Identification
NCT01311440	Not specified	COMPLETED	Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy
NCT01432821	Not specified	COMPLETED	Blinking and Yawning in Epilepsy: The Role of Dopamine
NCT03368469	Not specified	WITHDRAWN	Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression
NCT03457961	Not specified	UNKNOWN	Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
NCT03955432	Not specified	TERMINATED	Long-term Cardiac Monitoring in Epilepsy
NCT04252846	Not specified	COMPLETED	A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
NCT04965571	Not specified	COMPLETED	Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients
NCT05374928	Not specified	ACTIVE_NOT_RECRUITING	Human Epilepsy Project 3
NCT05530109	Not specified	TERMINATED	Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.
NCT06388174	Not specified	RECRUITING	Idiopathic Generalized Epilepsy Syndromes
NCT06797791	Not specified	COMPLETED	Assessment of Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation (cTBS) Effects in Generalized Epilepsy Patients.
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns
NCT03817515	Not specified	APPROVED_FOR_MARKETING	Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation